Skip Navigation
Skip to contents

Epidemiol Health : Epidemiology and Health

OPEN ACCESS
SEARCH
Search
Advanced Search
mobile menu button

Search

Page Path
HOME > Search
9 "Mina Suh"
Filter
Filter
Article category
Keywords
More +
Publication year
Authors
More +
Funded articles
Original Articles
Socioeconomic inequality in organized and opportunistic screening for colorectal cancer: results from the Korean National Cancer Screening Survey, 2009-2021
Xuan Quy Luu, Kyeongmin Lee, Jae Kwan Jun, Mina Suh, Kui Son Choi
Epidemiol Health. 2023;45:e2023086.   Published online September 17, 2023
DOI: https://doi.org/10.4178/epih.e2023086
  • 4,287 View
  • 133 Download
  • 1 Crossref
AbstractAbstract AbstractSummary PDFSupplementary Material
Abstract
OBJECTIVES
This study aimed to investigate socioeconomic status (SES)-based inequality in colorectal cancer (CRC) screening in Korea. We assessed whether the rates of opportunistic and organized CRC screening differed according to income and education levels.
METHODS
We analyzed data from the Korean National Cancer Screening Survey of 27,654 cancer-free individuals, aged 50-74 years, from 2009 to 2021. The weighted cancer screening rates with trends were estimated with the average annual percentage change using joinpoint regression. Inequality was calculated in both relative and absolute terms, based on a Poisson regression model.
RESULTS
The organized screening rate increased significantly from 22.1% in 2009 to 53.1% in 2020 and 50.6% in 2021, with an average annual change of 8.6% (95% confidence interval [CI], 4.9 to 12.5). In contrast, no significant trend was observed for opportunistic screening. The SES inequality in opportunistic screening uptake was indicated by a slope index of inequality (SII) of 9.74% (95% CI, 6.36 to 13.12), relative index of inequality (RII) of 2.18 (95% CI, 1.75 to 2.70) in terms of education level; and an SII of 7.03% (95% CI, 4.09 to 9.98), RII of 1.81 (95% CI, 1.41 to 2.31) in terms of measured income. Although there was an increasing trend in income inequality, no significant SES inequalities were observed in the overall estimates for organized screening.
CONCLUSIONS
Organized CRC screening is effective in improving the participation rate, regardless of SES. However, significant inequalities were found in opportunistic screening, suggesting room for improvement in the overall equity of CRC screening.
Summary
Korean summary
이번 연구는 한국의 대장암 검진에서 사회경제적 수준에 따른 불평등이 있는지를 분석했다. 국가암검진사업 도입 이래로 2009-2021년 연구기간 동안 공공검진을 통한 대장암 수검률은 지속적으로 증가한 반면, 개인검진의 증가는 관찰되지 않았다. 특히 공공 검진의 경우 소득이나 교육수준에 따른 수검률에 차이는 없는 반면, 개인검진에서는 상당한불평등이 관찰되었다.
Key Message
"The study investigated socioeconomic status (SES)-based inequality in colorectal cancer (CRC) screening in Korea. We found that the introduction of the National Cancer Screening Program for CRC effectively increased the participation rate, regardless of the SES of the individuals throughout the study period. However, significant inequalities were observed in opportunistic screening related to education and income."

Citations

Citations to this article as recorded by  
  • Disparities in Cancer Incidence across Income Levels in South Korea
    Su-Min Jeong, Kyu-Won Jung, Juwon Park, Nayeon Kim, Dong Wook Shin, Mina Suh
    Cancers.2023; 15(24): 5898.     CrossRef
Parental intention to vaccinate daughters with the human papillomavirus vaccine in Korea: a nationwide cross-sectional survey
Yejin Ha, Kyeongmin Lee, Bomi Park, Mina Suh, Jae Kwan Jun, Kui Son Choi
Epidemiol Health. 2023;45:e2023076.   Published online August 17, 2023
DOI: https://doi.org/10.4178/epih.e2023076
  • 2,669 View
  • 114 Download
AbstractAbstract AbstractSummary PDF
Abstract
OBJECTIVES
We aimed to identify and compare the characteristics and factors associated with parental intention to vaccinate daughters under 12 years old against human papillomavirus (HPV), examining data from 2016 and 2020.
METHODS
Data were obtained from the Korean National Cancer Screening Survey conducted in 2016 and 2020. The present study included 3,510 parents with daughters under 12 years old. Changes in parental intention-to-vaccinate rates were calculated. To identify factors associated with parental intention to vaccinate their daughters, the chi-square test and logistic regression analysis were used.
RESULTS
The percentage of respondents intending to vaccinate their daughters increased from 33.4% in 2016 to 58.9% in 2020, constituting a 25.5 percentage point (%p) increase. Since 2016, the proportion of men expressing positive intention towards HPV vaccination increased by 31.5%p, while that of women demonstrated a 20.9%p increase. Logistic regression analysis indicated that parents with a strong intention to vaccinate their daughters tended to be younger, more educated, and aware of the free vaccination program available, as well as to have a history of HPV vaccination and to have undergone cervical cancer screening within 2 years, compared to those who did not intend to vaccinate. Being a mother with a history of HPV vaccination was the strongest predictor of positive intention to vaccinate a daughter.
CONCLUSIONS
The intention among parents to vaccinate daughters remains relatively low, although it is rising. To increase the HPV vaccination rate, strong recommendations and education should be provided to parents and the younger generation.
Summary
Korean summary
한국정부는 2016년부터 HPV 백신을 국가예방접종사업으로 도입하여 만 12세 여아를 대상으로 무료접종을 실시하고 있다. 12세 여아가 접종대상인만큼 부모의 HPV 백신에 대한 인식과 태도가 실제 예방접종에 중요한 영향을 미친다. 이 연구를 통해 2016년과 2020년을 비교했을 때 딸의 백신접종에 대한 의향이 증가하였음을 알 수 있었고, 특히 HPV 백신접종 경험이 있는 경우 딸의 백신접종에 대한 의향이 유의하게 높음을 확인하였다.
Key Message
In Korea, HPV vaccination was included in the national immunization program in 2016 for 12-year-old girls. The decision to undergo the HPV vaccination is closely associated with their parents’ perceptions of and attitudes toward the HPV vaccine. This study identified that parental intention increased from 2016 to 2020, and maternal history of HPV vaccination was the strongest predictor of positive intention to vaccinate a daughter.
Trends in breast cancer screening rates among Korean women: results from the Korean National Cancer Screening Survey, 2005-2020
Soo Yeon Song, Yun Yeong Lee, Hye Young Shin, Bomi Park, Mina Suh, Kui Son Choi, Jae Kwan Jun
Epidemiol Health. 2022;44:e2022111.   Published online November 24, 2022
DOI: https://doi.org/10.4178/epih.e2022111
  • 3,347 View
  • 147 Download
  • 2 Web of Science
  • 2 Crossref
AbstractAbstract AbstractSummary PDFSupplementary Material
Abstract
OBJECTIVES
Since 2002, the Korean government has provided breast cancer screening as part of the National Cancer Screening Program. This study reported trends in the screening rate among Korean women from 2005 to 2020, including organized and opportunistic screening for breast cancer.
METHODS
Data from the Korean National Cancer Screening Survey, an annual cross-sectional nationwide survey, were collected using a structured questionnaire between 2005 and 2020. The study population included 23,702 women aged 40-74 years with no history of cancer. We estimated the screening rate based on the current recommendation of biennial mammographic screening for breast cancer. In addition, a joinpoint trend analysis was performed for breast cancer screening rates among various subgroups.
RESULTS
In 2020, the breast cancer screening rate was 63.5%, reflecting an annual increase of 7.72% (95% confidence interval 5.53 to 9.95) between 2005 and 2012, followed by non-significant trends thereafter. In particular, a significant decrease in the breast cancer screening rate was observed in the subgroups aged 50-59 years old, with 12-15 years of education, and living in rural areas.
CONCLUSIONS
Although there has been substantial improvement in breast cancer screening rates in Korean women, the trend has flattened in recent years. Therefore, continual efforts are required to identify subgroups with unmet needs and solve barriers to the uptake of breast cancer screening.
Summary
Korean summary
본 연구는 2005년에서 2020년까지 암검진수검행태조사 자료를 이용하여 40세 이상의 우리나라 여성의 유방암 검진 수검률이 추이에 대해 분석하였다. 우리나라 유방암 검진 수검률은 2020년 현재 63.5%이다. 하지만 지속적으로 증가하던 유방암 검진 수검률의 추이는 2012년 이후 정체되어 있으며 일부 사회경제적 계층에서는 감소하는 경향을 보였다.
Key Message
In Korea, despite of the high level of breast cancer screening rate, decreasing trends in some socioeconomic classes after 2012. Continual efforts are required to identify subgroup with unmet needs and barriers to the uptake of breast cancer screening.

Citations

Citations to this article as recorded by  
  • Why is the screening rate in lung cancer still low? A seven-country analysis of the factors affecting adoption
    Charlotte Poon, Tim Wilsdon, Iqra Sarwar, Alexander Roediger, Megan Yuan
    Frontiers in Public Health.2023;[Epub]     CrossRef
  • Mammographic Breast Density and Risk of Ovarian Cancer in Korean Women
    Thi Xuan Mai Tran, Soyeoun Kim, Boyoung Park
    Cancer Epidemiology, Biomarkers & Prevention.2023; 32(12): 1690.     CrossRef
Effect of mammography screening on the long-term survival of breast cancer patients: results from the National Cancer Screening Program in Korea
Xuan Quy Luu, Kyeongmin Lee, Jae Kwan Jun, Mina Suh, Kyu-Won Jung, Kui Son Choi
Epidemiol Health. 2022;44:e2022094.   Published online October 26, 2022
DOI: https://doi.org/10.4178/epih.e2022094
  • 3,717 View
  • 162 Download
AbstractAbstract PDFSupplementary Material
Abstract
OBJECTIVES
This study investigated the effect of mammography screening on the long-term survival of breast cancer (BC) patients aged 40 years or older according to their screening history and duration since screening.
METHODS
The study cohort was organized from 3 nationwide databases of the Korean National Cancer Screening Program, the Korean Central Cancer Registry, and death certificates. We included 24,387 women diagnosed with invasive BC or ductal carcinoma in situ in 2008 and 2009 and followed up until December 31, 2019. Cox proportional-hazards regression was used to investigate the effect of BC screening on the risk of death.
RESULTS
Overall, 20,916 of 24,387 patients (85.8%) were alive at the end of the follow-up period (median: 10.5 years). The long-term survival rate was significantly lower in the never-screened group (80.3%) than in the screened group (88.9%) (p<0.001). A 35% reduction in the risk of BC death (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.60 to 0.70) from screening was observed. A subgroup analysis according to the cancer stage showed 62%, 36%, and 24% lower risks of BC death for the localized stage, regional stage, and distant stage, respectively. Women aged 40-49 years received the least benefit from BC screening (HR, 0.71; 95% CI, 0.62 to 0.81).
CONCLUSIONS
Mammography screening was effective in reducing the risk of BC-specific death in Asian women across all cancer stages. However, this effect was relatively small among women in their 40s, suggesting that more detailed and specialized screening strategies are needed for that age group.
Summary
Effect of Pap smears on the long-term survival of cervical cancer patients: a nationwide population-based cohort study in Korea
Xuan Quy Luu, Kyeongmin Lee, Jae Kwan Jun, Mina Suh, kyu-won Jung, Myong Cheol Lim, Kui Son Choi
Epidemiol Health. 2022;44:e2022072.   Published online September 7, 2022
DOI: https://doi.org/10.4178/epih.e2022072
  • 3,812 View
  • 101 Download
AbstractAbstract AbstractSummary PDFSupplementary Material
Abstract
OBJECTIVES
This study aimed to investigate the effect of cervical cancer screening by Papanicolaou (Pap) smears on the long-term survival of cervical cancer patients.
METHODS
We constructed a retrospective cohort of 14,903 women diagnosed with invasive cancer or carcinoma in situ in 2008 and 2009 and followed up until December 31, 2019, by using individual-level data from 3 national databases of the Korean National Cancer Screening Program, the Korean Central Cancer Registry, and death certificates. Cox proportional-hazards regression was used to investigate the effect of cervical cancer screening on mortality.
RESULTS
In total, 12,987 out of 14,867 patients (87.4%) were alive at the end of the follow-up period (median: 10.5 years). Screened patients had a 38% lower risk of cervical cancer death than never-screened patients (hazard ratio [HR], 0.62; 95% confidence interval [CI], 0.54 to 0.70). Screening was associated with 59% and 35% lower risks of death, respectively, in screened patients with localized and regional stages. Furthermore, lower HRs among women who received screening were observed in all age groups, especially women aged 50–59 years (HR, 0.54; 95% CI, 0.42 to 0.69). The lowest HR for cervical cancer death was reported among patients screened within the past 2 years (HR, 0.54; 95% CI, 0.47 to 0.63), and the HRs increased with increasing time intervals.
CONCLUSIONS
Pap smear screening significantly reduced the risk of cervical cancer-specific death in Korean women across all cancer stages.
Summary
Korean summary
한국은 자궁경부암 발생과 사망을 낮추기 위하여 국가암검진사업으로 자궁경부암 검진을 실시하고 있다. 이 연구는 2008-2009년 자궁경부암 진단을 받은 30세-79세 14,903명을 대상으로 과거 자궁경부세포검진 여부에 따른 장기생존율을 추적 조사하였다. 그 결과 자궁경부암 검진을 받은 환자에서 사망 위험비가 약 38% 낮았으며, 2년 이내에 검진을 받은 환자군에서 사망 위험이 가장 낮았다.
Key Message
The Korean National Cancer Screening Program (KNCSP) has provided cervical cancer screening by Pap smear test. However, the survival, particularly long-term survival of cervical cancer patients, has never been evaluated in the KNCSP. This study reports a significant improvement in the long-term survival of screened cervical cancer patients, which persist in subgroup analysis by cancer stage. Patients who were screened within two years before the diagnosis had the best survival.
Changes in cancer screening before and during COVID‐19: findings from the Korean National Cancer Screening Survey 2019 and 2020
Thao Thi Kim Trinh, Yun Yeong Lee, Mina Suh, Jae Kwan Jun, Kui Son Choi
Epidemiol Health. 2022;44:e2022051.   Published online May 30, 2022
DOI: https://doi.org/10.4178/epih.e2022051
  • 8,072 View
  • 365 Download
  • 2 Web of Science
  • 1 Crossref
AbstractAbstract AbstractSummary PDFSupplementary Material
Abstract
OBJECTIVES
The coronavirus disease 2019 (COVID-19) pandemic has negatively affected every aspect of medical care. However, information regarding the impact of the pandemic on cancer screening is lacking. This study aimed to explore cancer screening changes by geographic region before and during the pandemic in Korea.
METHODS
Korean National Cancer Screening Survey data for 2019 and 2020 were used. Changes in the screening rate before and during the COVID-19 pandemic were calculated by subtracting the rate in 2020 from the rate in 2019. Multivariate logistic regression analyses examined the differences in screening rates at the national and 16 provincial levels before and after the COVID-19 outbreak.
RESULTS
The 1-year screening rates for the four types of cancer decreased during the pandemic (stomach cancer: -5.1, colorectal cancer: -3.8, breast cancer: -2.5, cervical cancer: -1.5%p). In metropolitan areas, the odds of undergoing screening tests during the pandemic were significantly lower than before the pandemic for stomach (adjusted odds ratio [aOR], 0.66; 95% confidence interval [CI], 0.56 to 0.76), colorectal (aOR, 0.63; 95% CI, 0.50 to 0.79), and breast cancers (aOR, 0.75; 95% CI, 0.60 to 0.94). Furthermore, the likelihood of undergoing stomach cancer screening during the pandemic was significantly lower than before the pandemic in non-metropolitan urban areas (aOR, 0.81; 95% CI, 0.70 to 0.94), while it was higher in rural areas (aOR, 1.54; 95% CI, 1.10 to 2.16).
CONCLUSIONS
Since the COVID-19 pandemic, the cancer screening rate has decreased significantly, especially in large cities. Public health efforts are required to improve cancer screening rates.
Summary
Korean summary
• 코로나 대유행 이전과 이후의 최근 1년간 암검진 수검률을 비교한 결과, 위암 (5% 포인트), 대장암 (3.8% 포인트), 유방암 (2.5% 포인트), 자궁경부암 (1.5% 포인트) 수검률이 통계적으로 유의하게 감소하였음 • 특히 위암, 대장암, 유방암의 경우 대도시 지역에서의 수검률이 현저하게 감소하였음
Key Message
The 1-year screening rates for stomach, colorectal, breast, and cervical cancer decreased significantly during the pandemic in Korea, especially in large cities.

Citations

Citations to this article as recorded by  
  • Mining Google Trends data for nowcasting and forecasting colorectal cancer (CRC) prevalence
    Cristiana Tudor, Robert Aurelian Sova
    PeerJ Computer Science.2023; 9: e1518.     CrossRef
Physician’s awareness of lung cancer screening and its related medical radiation exposure in Korea
Seri Hong, Suyeon Kim, Mina Suh, Boyoung Park, Kui Son Choi, Jae Kwan Jun
Epidemiol Health. 2018;40:e2018002.   Published online January 20, 2018
DOI: https://doi.org/10.4178/epih.e2018002
  • 14,910 View
  • 263 Download
  • 3 Web of Science
  • 2 Crossref
AbstractAbstract AbstractSummary PDFSupplementary Material
Abstract
OBJECTIVES
Through a survey on perception of lung cancer screening and accompanying medical radiation exposure in Korea, the present study was to investigate its current situations and evaluate various perception of physicians regarding it in order to propose measures for improvements.
METHODS
Medical specialists in national cancer screening institutions selected through stratified random sampling were subjected to face-to-face interview using a structured questionnaire. We investigated physicians’ perception on effectiveness of lung cancer screening depending on screening modality, selection criteria for subjects of screening, types of equipment used to screen, and perception for seriousness of adverse effects following the test. In addition, odds ratios to underestimate risk of radiation exposure from screening were calculated through logistic regression analysis.
RESULTS
Each response that chest X-ray is effective for lung cancer screening and that smoking history is not considered prior to screening recommendation accounted for more than 60% of respondents, suggesting the chance of unnecessary screening tests. Regarding adverse effects of lung cancer screening, about 85% of respondents replied that false positive, radiation exposure, and overdiagnosis could be ignored. About 70% of respondents underestimated radiation dose from lung cancer screening, and a low proportion of physicians informed patients of radiation exposure risk.
CONCLUSIONS
It was found that most physicians underestimated harms of lung cancer screening including radiation exposure and were lack of awareness regarding lung cancer screening. It should be noted that physicians need to have proper perceptions about screening recommendation and accompanying possible harms, for successful implementation of the screening program.
Summary
Korean summary
전국 100여개 국가암검진 기관을 대상으로 폐암검진 관련 설문을 수행한 결과, 효과적인 폐암검진의 수단이나 방법에 대한 이해 및 검사에 수반되는 각종 부작용에 대한 의사들의 인식이 확연히 부족한 것으로 조사되었다. 그 중에서도 특히 의료방사선 노출에 대한 낮은 인지도는, 촬영 시 피폭량에 대한 전반적인 과소평가 및 방사선 노출 위험과 관련한 환자 교육의 부재를 통해 확인할 수 있었다. 인구집단 대상 선별검사의 도입에 따른 잠재적인 위해 가능성과 그 결과에 대한 고민은 반드시 필요하며, 이와 관련된 의료제공자들의 인식 개선을 촉구하는 본 연구는 정책 도입에 앞서 선결되어야 할 과제로서 공중보건학적 측면에서 중요한 의의를 지닌다.

Citations

Citations to this article as recorded by  
  • Why is the screening rate in lung cancer still low? A seven-country analysis of the factors affecting adoption
    Charlotte Poon, Tim Wilsdon, Iqra Sarwar, Alexander Roediger, Megan Yuan
    Frontiers in Public Health.2023;[Epub]     CrossRef
  • Why clinicians overtest: development of a thematic framework
    Justin H. Lam, Kristen Pickles, Fiona F. Stanaway, Katy J. L. Bell
    BMC Health Services Research.2020;[Epub]     CrossRef
Cancer screening rate in people with diabetes in the Korean population: results from the Korea National Health and Nutrition Examination Survey 2007-2009
Kumban Walter Chuck, Minji Hwang, Kui Son Choi, Mina Suh, Jae Kwan Jun, Boyoung Park
Epidemiol Health. 2017;39:e2017036.   Published online August 10, 2017
DOI: https://doi.org/10.4178/epih.e2017036
  • 13,204 View
  • 257 Download
  • 13 Web of Science
  • 15 Crossref
AbstractAbstract AbstractSummary PDF
Abstract
OBJECTIVES
To investigate the screening rates for gastric, breast, and cervical cancer in people with diabetes compared with people without diabetes.
METHODS
Data from the Korea National Health and Nutrition Examination Survey (2007-2009) were used. Cancer-free men who were 40 years old and over and cancer-free women who were 30 years old and over were included. The lifetime screening rate and regular screening rate were compared in people with and without diabetes.
RESULTS
Fewer people with diabetes than people without diabetes had ever received cancer screening (53.5 vs. 59.5%, p<0.001 for gastric cancer; 60.5 vs. 71.5%, p<0.001 for breast cancer; and 49.1 vs. 59.6%, p<0.001 for cervical cancer). Fewer people with diabetes than people without diabetes received the recommended screenings for gastric cancer (38.9 vs. 42.9%, p<0.001), breast cancer (38.8 vs. 44.6%, p<0.001), and cervical cancer (35.1 vs. 51.2%, p<0.001). In subgroup analyses according to socioeconomic factors, the lifetime and recommended screening rates were lower in the diabetic population in most socioeconomic subgroups. In the multivariate analysis adjusted for socioeconomic factors, people with diabetes showed lower lifetime screening rates for gastric and cervical cancer (odds ratio [OR], 0.8; 95% confidence interval [CI], 0.7 to 0.9 and OR, 0.7; 95% CI, 0.6 to 0.9), and lower regular screening rates for breast and cervical cancer (OR, 0.7; 95% CI, 0.6 to 0.9 and OR, 0.7; 95% CI, 0.5 to 0.9).
CONCLUSIONS
The cancer screening rate in people with diabetes was lower than in people without diabetes. Considering the higher cancer risk in people with diabetes, efforts to increase the screening rate in this high-risk population should be implemented.
Summary
Korean summary
기존의 여러 연구에서 당뇨병이 있는 사람에서 당뇨병이 없는 경우에 비해 암 발생의 위험이 증가하는 것이 확인되었다. 본 연구에서 당뇨병이 있는 사람과 없는 사람에서 암 수검률을 비교했을 때, 당뇨병이 있는 사람의 위암, 유방암, 자궁경부암의 평생 수검률과 권고안 이행 수검률은 모두 낮았다. 당뇨병 환자가 암 발생의 고위험군임을 고려하였을 때 이들을 대상으로 암 검진 수검률을 높이려는 노력이 필요하다.

Citations

Citations to this article as recorded by  
  • Typ-2-Diabetes mellitus und gastrointestinale Krebsvorsorge
    Hans Scherübl
    Zeitschrift für Gastroenterologie.2023; 61(06): 683.     CrossRef
  • Increased Breast and Colorectal Cancer Risk in Type 2 Diabetes: Awareness Among Adults With and Without Diabetes and Information Provision on Diabetes Websites
    Laura Ashley, Kathryn A Robb, Daryl B O’Connor, Rebecca Platt, Mollie Price, Olivia Robinson, Elizabeth Travis, Lorraine Lipscombe, Ramzi Ajjan, Rebecca Birch
    Annals of Behavioral Medicine.2023; 57(5): 386.     CrossRef
  • Diabetes and Cancer
    Jae Won Hong
    The Journal of Korean Diabetes.2023; 24(1): 12.     CrossRef
  • Diabetes mellitus and cancer
    Jae Won Hong
    Cardiovascular Prevention and Pharmacotherapy.2023; 5(3): 69.     CrossRef
  • More new cancers in type 2 diabetes with diabetic foot disease: A longitudinal observational study
    Fadi Alkhami, Gauthier Borderie, Ninon Foussard, Alice Larroumet, Laurence Blanco, Marie-Amélie Barbet-Massin, Amandine Ferrière, Claire Ducos, Frédéric Domenge, Kamel Mohammedi, Vincent Rigalleau
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(10): 102859.     CrossRef
  • Do diabetic complications influence cancer-related events in people with type 2 diabetes? A cohort approach
    Evelyne Liuu, Pierre-Jean Saulnier, Elise Gand, Gautier Defossez, Amélie Jamet, Stéphanie Ragot, Marc Paccalin, Samy Hadjadj
    Diabetes & Metabolism.2022; 48(2): 101289.     CrossRef
  • Factors associated with adherence to colonoscopy among individuals who were positive in the preliminary screening for colorectal neoplasms
    Ji‐Bin Li, Keng‐Jian Ke, Wei‐Li Zhang, Ling‐Yan Wang, Yan‐Ping Wu, Fan Weng, Huan Tian, Zhi‐Yu Qiu, Yin Li, Shi‐Yong Lin, Mei‐Xian Ye, Qing‐Jian Ou, Cheng‐Hua Gong, Zhen‐Hai Lu, Zhi‐Zhong Pan, De‐Sen Wan, Jian‐Hong Peng, Yu‐Jing Fang
    Cancer Medicine.2022; 11(22): 4321.     CrossRef
  • Prediction Model for Hypertension and Diabetes Mellitus Using Korean Public Health Examination Data (2002–2017)
    Yong Whi Jeong, Yeojin Jung, Hoyeon Jeong, Ji Hye Huh, Ki-Chul Sung, Jeong-Hun Shin, Hyeon Chang Kim, Jang Young Kim, Dae Ryong Kang
    Diagnostics.2022; 12(8): 1967.     CrossRef
  • Typ-2-Diabetes mellitus und gastrointestinale Krebsvorsorge
    Hans Scherübl
    Diabetes aktuell.2022; 20(06): 287.     CrossRef
  • The Relationship between Diabetes Mellitus and Gastric Cancer and the Potential Benefits of Metformin: An Extensive Review of the Literature
    Chin-Hsiao Tseng
    Biomolecules.2021; 11(7): 1022.     CrossRef
  • Type 2 diabetes and colorectal cancer screening: Findings from the English Longitudinal Study of Ageing
    Christian von Wagner, Dorina Cadar, Ruth A Hackett, Panayotes Demakakos, Rebecca J Beeken, Stacy Cooper Bailey, Michael Wolf, Andrew Steptoe, Cristina Renzi, Sandro T Stoffel
    Journal of Medical Screening.2020; 27(1): 25.     CrossRef
  • Breast, cervical and colorectal cancer screening in adults with diabetes: a systematic review and meta-analysis
    Dominika Bhatia, Iliana C. Lega, Wei Wu, Lorraine L. Lipscombe
    Diabetologia.2020; 63(1): 34.     CrossRef
  • Review: Diabetes, Obesity, and Cancer—Pathophysiology and Clinical Implications
    Iliana C Lega, Lorraine L Lipscombe
    Endocrine Reviews.2020; 41(1): 33.     CrossRef
  • The Incidences and Characteristics of Various Cancers in Patients on Dialysis: a Korean Nationwide Study
    Soon Kil Kwon, Joung-Ho Han, Hye-Young Kim, Gilwon Kang, Minseok Kang, Yeonkook J. Kim, Jinsoo Min
    Journal of Korean Medical Science.2019;[Epub]     CrossRef
  • Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment
    Sunghwan Suh, Kwang-Won Kim
    Diabetes & Metabolism Journal.2019; 43(6): 733.     CrossRef
Cancer mortality-to-incidence ratio as an indicator of cancer management outcomes in Organization for Economic Cooperation and Development countries
Eunji Choi, Sangeun Lee, Bui Cam Nhung, Mina Suh, Boyoung Park, Jae Kwan Jun, Kui Son Choi
Epidemiol Health. 2017;39:e2017006.   Published online February 5, 2017
DOI: https://doi.org/10.4178/epih.e2017006
  • 18,283 View
  • 448 Download
  • 77 Web of Science
  • 76 Crossref
AbstractAbstract PDF
Abstract
OBJECTIVES
Assessing long-term success and efficiency is an essential part of evaluating cancer control programs. The mortality-to-incidence ratio (MIR) can serve as an insightful indicator of cancer management outcomes for individual nations. By calculating MIRs for the top five cancers in Organization for Economic Cooperation and Development (OECD) countries, the current study attempted to characterize the outcomes of national cancer management policies according to the health system ranking of each country.
METHODS
The MIRs for the five most burdensome cancers globally (lung, colorectal, prostate, stomach, and breast) were calculated for all 34 OECD countries using 2012 GLOBOCAN incidence and mortality statistics. Health system rankings reported by the World Health Organization in 2000 were updated with relevant information when possible. A linear regression model was created, using MIRs as the dependent variable and health system rankings as the independent variable.
RESULTS
The linear relationships between MIRs and health system rankings for the five cancers were significant, with coefficients of determination ranging from 49 to 75% when outliers were excluded. A clear outlier, Korea reported lower-than-predicted MIRs for stomach and colorectal cancer, reflecting its strong national cancer control policies, especially cancer screening.
CONCLUSIONS
The MIR was found to be a practical measure for evaluating the long-term success of cancer surveillance and the efficacy of cancer control programs, especially cancer screening. Extending the use of MIRs to evaluate other cancers may also prove useful.
Summary

Citations

Citations to this article as recorded by  
  • Global burden of 34 cancers among women in 2020 and projections to 2040: Population‐based data from 185 countries/territories
    Habtamu Mellie Bizuayehu, Abel F. Dadi, Tahir A. Hassen, Daniel Bekele Ketema, Kedir Y. Ahmed, Zemenu Y. Kassa, Erkihun Amsalu, Getiye Dejenu Kibret, Addisu Alehegn Alemu, Animut Alebel, Jemal E. Shifa, Yibeltal Assefa, Gizachew A. Tessema, Peter Sarich,
    International Journal of Cancer.2024; 154(8): 1377.     CrossRef
  • Gastric cancer screening in Western countries: A call to action
    Fabio Farinati, Filippo Pelizzaro
    Digestive and Liver Disease.2024;[Epub]     CrossRef
  • Development, acceptability and usability of culturally appropriate survivor narrative videos for breast cancer treatment in Botswana: a pilot study
    Yehoda M Martei, Lebogang Mokokwe, Ngwao Ngwako, Keaobaka Kebuang, Dipho I Setlhako, Goitsemang Gabaatlhole, Bontswanetse Baaitse, Tumisang Segadimo, Lawrence N Shulman, Frances Barg, Babe E Gaolebale
    BMJ Open.2024; 14(1): e073867.     CrossRef
  • Disparities in mortality risk after diagnosis of hematological malignancies in 185 countries: A global data analysis
    Jing Yang, Xin Liu, Qiu-Zi Zhong, Yong Yang, Tao Wu, Si-Ye Chen, Bo Chen, Yong-Wen Song, Hui Fang, Shu-Lian Wang, Yue-Ping Liu, Jing Jin, Ning Li, Ning-Ning Lu, Hao Jing, Yuan Tang, Fan Chen, Xi-Mei Zhang, Wenwen Zhang, Yirui Zhai, Shu-Nan Qi, Ye-Xiong Li
    Cancer Letters.2024; : 216793.     CrossRef
  • Utility of auto fluorescence-guided biopsy in suspected lung cancer patients with bronchial mucosal lesions
    Gaozhe Wang, Yan Jin, Kunlong Xiong, Xiaoyan Jin, Linfeng Wang, Chenwei Li
    Photodiagnosis and Photodynamic Therapy.2024; 46: 104057.     CrossRef
  • Policy strategies for capacity building and scale up of the workforce for comprehensive cancer care: a systematic review
    D. Trapani, S.S. Murthy, N. Hammad, R. Casolino, D.C. Moreira, F. Roitberg, J.-Y. Blay, G. Curigliano, A.M. Ilbawi
    ESMO Open.2024; 9(4): 102946.     CrossRef
  • Global, regional, and national burdens of early onset pancreatic cancer in adolescents and adults aged 15–49 years from 1990 to 2019 based on the Global Burden of Disease Study 2019: a cross-sectional study
    Zheng Li, Xiaojie Zhang, Chongyuan Sun, Zefeng Li, He Fei, Dongbing Zhao
    International Journal of Surgery.2024; 110(4): 1929.     CrossRef
  • Self-Assembly of Peptides as an Alluring Approach toward Cancer Treatment and Imaging
    Muhammad Hamza Ghafoor, Ben-Li Song, Lei Zhou, Zeng-Ying Qiao, Hao Wang
    ACS Biomaterials Science & Engineering.2024;[Epub]     CrossRef
  • Global, regional, and national trends of dementia incidence and risk factors, 1990–2019: A Global Burden of Disease study
    Abolfazl Avan, Vladimir Hachinski
    Alzheimer's & Dementia.2023; 19(4): 1281.     CrossRef
  • Improved Trends in the Mortality-to-Incidence Ratios for Liver Cancer in Countries with High Development Index and Health Expenditures
    Chang-Cheng Su, Brian-Shiian Chen, Hsin-Hung Chen, Wen-Wei Sung, Chi-Chih Wang, Ming-Chang Tsai
    Healthcare.2023; 11(2): 159.     CrossRef
  • Updated epidemiology of gastrointestinal cancers in East Asia
    Junjie Huang, Don Eliseo Lucero-Prisno, Lin Zhang, Wanghong Xu, Sunny H. Wong, Siew C. Ng, Martin C. S. Wong
    Nature Reviews Gastroenterology & Hepatology.2023; 20(5): 271.     CrossRef
  • Peptide Self-Assembled Nanocarriers for Cancer Drug Delivery
    Vijay Bhooshan Kumar, Busra Ozguney, Anastasia Vlachou, Yu Chen, Ehud Gazit, Phanourios Tamamis
    The Journal of Physical Chemistry B.2023; 127(9): 1857.     CrossRef
  • Stigma and Social Determinants of Health Associated With Fidelity to Guideline-Concordant Therapy in Patients With Breast Cancer Living With and Without HIV in Botswana
    Yehoda M Martei, Modesty Obasohan, Lebogang Mokokwe, Tlotlo Ralefala, Mosepele Mosepele, Robert Gross, Frances K Barg
    The Oncologist.2023; 28(12): e1230.     CrossRef
  • Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel
    Joanne Wing Yan Chiu, Soo Chin Lee, James Chung-man Ho, Yeon Hee Park, Ta-Chung Chao, Sung-Bae Kim, Elgene Lim, Ching-Hung Lin, Sherene Loi, Su Ying Low, Lynette Li San Teo, Winnie Yeo, Rebecca Dent
    Drug Safety.2023; 46(10): 927.     CrossRef
  • Gender differences in leukemia outcomes based on health care expenditures using estimates from the GLOBOCAN 2020
    Maedeh Amini, Rajesh Sharma, Chinmay Jani
    Archives of Public Health.2023;[Epub]     CrossRef
  • Unfavorable cancer mortality‐to‐incidence ratios in patients with schizophrenia: A nationwide cohort study in Taiwan, 2000–2019
    Chu‐Syuan Cheng, Wen‐Yin Chen, Hu‐Ming Chang, Chun‐Hung Pan, Sheng‐Siang Su, Shang‐Ying Tsai, Chiao‐Chicy Chen, Chian‐Jue Kuo
    Acta Psychiatrica Scandinavica.2023; 148(4): 347.     CrossRef
  • Mortality‐to‐incidence ratio of early‐onset colorectal cancer in high‐income Asian and Middle Eastern countries: A systemic analysis of the Global Burden of Diseases Study 2019
    Majed Ramadan, Rawiah A. Alsiary, Doaa A. Aboalola
    Cancer Medicine.2023; 12(21): 20604.     CrossRef
  • Spiritual coping strategies: Relationship with physical, anxiety, and depression symptoms of patients with cancer
    Atefeh Ahmadi, Aazam Heidarzadeh, Mahlagha Dehghan, Mohammah Hossein Safarizadeh, Mansooreh Azizzadeh Forouzi
    Indian Journal of Cancer.2023; 60(3): 439.     CrossRef
  • Assessing the quality of care for skin malignant melanoma on a global, regional, and national scale: a systematic analysis of the global burden of disease study from 1990 to 2019
    Mingjuan Liu, Mengyin Wu, Xintong Liu, Jia Zhou, Yining Lan, Hanlin Zhang, Xinyi zhang, Ling Leng, Heyi Zheng, Jun Li
    Archives of Dermatological Research.2023; 315(10): 2893.     CrossRef
  • The fraction of life years lost after diagnosis (FLYLAD): a person-centred measure of cancer burden
    David Banham, Jonathan Karnon, Alex Brown, David Roder, John Lynch
    Population Health Metrics.2023;[Epub]     CrossRef
  • Global trend analysis of diabetes mellitus incidence, mortality, and mortality-to-incidence ratio from 1990 to 2019
    Mohammadreza Balooch Hasankhani, Hossein Mirzaei, Ali Karamoozian
    Scientific Reports.2023;[Epub]     CrossRef
  • Burden of AML, 1990-2019: Estimates From the Global Burden of Disease Study
    Chinmay T. Jani, Alaaeldin Ahmed, Harpreet Singh, Christian Mouchati, Omar Al Omari, Padmanabh S. Bhatt, Rajesh Sharma, Minaam Farooq, Weitao Liu, Joseph Shalhoub, Dominic Marshall, Justin D. Salciccioli, Jeremy L. Warner, Prudence Lam
    JCO Global Oncology.2023;[Epub]     CrossRef
  • Type 1 diabetes mellitus disease burden in high health expenditure countries between 1990 and 2019
    Michael Edwards, Aurimas Kudzinskas, Andrew Alazawi, Will Hughes, Richard Goodall, Eleanor Harbinson, Justin Salciccioli, Dominic Marshall, Joseph Shalhoub
    Diabetes and Vascular Disease Research.2023;[Epub]     CrossRef
  • Spatial and temporal patterns of prostate cancer burden and their association with Socio‐Demographic Index in Asia, 1990–2019
    Li‐Sha Luo, Jun‐Feng Jiang, Hang‐Hang Luan, Hao Zi, Cong Zhu, Bing‐Hui Li, Xian‐Tao Zeng
    The Prostate.2022; 82(2): 193.     CrossRef
  • Cancer of unknown primary ‐ incidence, mortality trend, and mortality‐to‐incidence ratio is associated with human development index in Central Serbia, 1999–2018: Evidence from the national cancer registry
    Aleksandra Ignjatović, Miodrag Stojanović, Zoran Milošević, Marija Anđelković Apostolović, Tamara Filipović, Nataša Rančić, Roberta Marković, Marija Topalović, Dijana Stojanović, Suzana Otašević
    European Journal of Cancer Care.2022;[Epub]     CrossRef
  • Global, regional, and national burden and quality of care index of endocarditis: the global burden of disease study 1990–2019
    Sara Momtazmanesh, Sahar Saeedi Moghaddam, Elaheh Malakan Rad, Sina Azadnajafabad, Narges Ebrahimi, Esmaeil Mohammadi, Mahtab Rouhifard, Negar Rezaei, Masoud Masinaei, Nazila Rezaei, Mohammad Keykhaei, Arya Aminorroaya, Azin Ghamari, Bagher Larijani, Fars
    European Journal of Preventive Cardiology.2022; 29(8): 1287.     CrossRef
  • Global pattern of trends in incidence, mortality, and mortality-to-incidence ratio rates related to liver cancer, 1990–2019: a longitudinal analysis based on the global burden of disease study
    Maedeh Amini, Mehdi Azizmohammad Looha, Elaheh Zarean, Mohamad Amin Pourhoseingholi
    BMC Public Health.2022;[Epub]     CrossRef
  • Mapping Cancer in Africa: A Comprehensive and Comparable Characterization of 34 Cancer Types Using Estimates From GLOBOCAN 2020
    Rajesh Sharma, Aashima, Mehak Nanda, Claudio Fronterre, Paul Sewagudde, Anna E. Ssentongo, Kelsey Yenney, Nina D. Arhin, John Oh, Forster Amponsah-Manu, Paddy Ssentongo
    Frontiers in Public Health.2022;[Epub]     CrossRef
  • Cancer in sub-Saharan Africa in 2020: a review of current estimates of the national burden, data gaps, and future needs
    Freddie Bray, D Maxwell Parkin, Freddy Gnangnon, Gontse Tshisimogo, Jean-Felix Peko, Innocent Adoubi, Mathewos Assefa, Lamin Bojang, Baffour Awuah, Moussa Koulibaly, Nathan Buziba, Anne Korir, Charles Dzamalala, Bakarou Kamate, Shyam Manraj, Josefo Ferro,
    The Lancet Oncology.2022; 23(6): 719.     CrossRef
  • Burden of type 1 diabetes mellitus in the North Africa and Middle East Region, 1990–2019; findings from the global burden of disease study
    Shahnaz Esmaeili, Sahar Saeedi Moghaddam, Nazli Namazi, Fatemeh Bandarian, Zahra Esfahani, Maryam Peimani, Sarvenaz Shahin, Ensieh Nasli-Esfahani, Isa Akbarzadeh, Ali Ghanbari, Negar Rezaei, Nazila Rezaei, Bagher Larijani, Farshad Farzadfar
    Diabetes Research and Clinical Practice.2022; 188: 109912.     CrossRef
  • Cancer incidence and mortality and risk factors in member countries of the " Belt and Road " initiative
    Baohua Wang, Fengdie He, Yanan Hu, Qiutong Wang, Dan Wang, Yuting Sha, Jing Wu
    BMC Cancer.2022;[Epub]     CrossRef
  • Geographical Differences in Kidney Cancer Outcomes of Patients Treated with Immunotherapy: A Systematic Review
    Vinicius Knackfuss Gonçalves, Fernando Sabino Marques Monteiro, Antonia Angeli Gazola, Felipe Pizzolo, Júlia Elisa Hübner, Rodrigo Pellegrini, Alessandra Borba, André P. Fay
    Kidney Cancer.2022; 6(2): 129.     CrossRef
  • Global burden of disease study at the world health organization: research methods for the most comprehensive global study of disease and underlying health policies
    Lee Smith, Jae Il Shin, Soo Young Hwang, Kalthoum Tizaoui, Elena Dragioti, Louis Jacob, Karel Kostev, Seung Won Lee, Ai Koyanagi
    Life Cycle.2022;[Epub]     CrossRef
  • Quality of care of peptic ulcer disease worldwide: A systematic analysis for the global burden of disease study 1990–2019
    Mohsen Abbasi-Kangevari, Naser Ahmadi, Nima Fattahi, Negar Rezaei, Mohammad-Reza Malekpour, Seyyed-Hadi Ghamari, Sahar Saeedi Moghaddam, Sina Azadnajafabad, Zahra Esfahani, Ali-Asghar Kolahi, Shahin Roshani, Sahba Rezazadeh-Khadem, Fateme Gorgani, Seyyed
    PLOS ONE.2022; 17(8): e0271284.     CrossRef
  • A scoping review on population-centered indicators for cancer care continuum
    Vasuki Rajaguru, Jieun Jang, Jeoung A. Kwon, Jae Hyun Kim, Jaeyong Shin, Mison Chun
    Frontiers in Public Health.2022;[Epub]     CrossRef
  • COMPARISON OF TEMPORAL TRENDS IN THE GLOBAL BURDEN OF TRACHEA, BRONCHIAL, AND LUNG CANCER
    İskender ÇETİNTÜRK, Vahit YİĞİT
    Giresun Üniversitesi İktisadi ve İdari Bilimler Dergisi.2022; 8(2): 254.     CrossRef
  • ANALYSIS OF INCIDENCE AND MORTALITY OF GASTROINTESTINAL MALIGNANT TUMORS IN UKRAINE AND WORLDWIDE
    Valeriy Zub
    Acta Medica Leopoliensia.2022; 28(3-4): 22.     CrossRef
  • Global, regional, national burden of breast cancer in 185 countries: evidence from GLOBOCAN 2018
    Rajesh Sharma
    Breast Cancer Research and Treatment.2021; 187(2): 557.     CrossRef
  • A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990–2017
    Mohammad Keykhaei, Masood Masinaei, Esmaeil Mohammadi, Sina Azadnajafabad, Negar Rezaei, Sahar Saeedi Moghaddam, Nazila Rezaei, Maryam Nasserinejad, Mohsen Abbasi-Kangevari, Mohammad-Reza Malekpour, Seyyed-Hadi Ghamari, Rosa Haghshenas, Kamyar Koliji, Far
    Experimental Hematology & Oncology.2021;[Epub]     CrossRef
  • The global landscape of drug development of trastuzumab biosimilars
    Dario Trapani, Giuseppe Curigliano
    Journal of Cancer Policy.2021; 28: 100273.     CrossRef
  • Trend analysis of cardiovascular disease mortality, incidence, and mortality-to-incidence ratio: results from global burden of disease study 2017
    Maedeh Amini, Farid Zayeri, Masoud Salehi
    BMC Public Health.2021;[Epub]     CrossRef
  • Global, regional, and national burden and quality of care index (QCI) of thyroid cancer: A systematic analysis of the Global Burden of Disease Study 1990–2017
    Sina Azadnajafabad, Sahar Saeedi Moghaddam, Esmaeil Mohammadi, Negar Rezaei, Erfan Ghasemi, Nima Fattahi, Arya Aminorroaya, Reza Azadnajafabad, Armin Aryannejad, Nazila Rezaei, Shohreh Naderimagham, Vahid Haghpanah, Ali H. Mokdad, Hossein Gharib, Farshad
    Cancer Medicine.2021; 10(7): 2496.     CrossRef
  • National and Subnational Incidence, Mortality, and Years of Life Lost Due to Breast Cancer in Iran: Trends and Age-Period-Cohort Analysis Since 1990
    Bahar Ataeinia, Sahar Saeedi Moghaddam, Mahsima Shabani, Kimiya Gohari, Ali Sheidaei, Nazila Rezaei, Shohreh Naderimagham, Erfan Ghasemi, Mahtab Rouhifard Khalilabad, Shahin Roshani, Yosef Farzi, Farshad Farzadfar
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Honey and its protein components: Effects in the cancer immunology
    Ivan Chan‐Zapata, Maira Rubí Segura‐Campos
    Journal of Food Biochemistry.2021;[Epub]     CrossRef
  • A Comparison of the United States and Austrian Healthcare Needs and Systems
    Margaret McAlister, Joey D. Helton
    INQUIRY: The Journal of Health Care Organization, Provision, and Financing.2021; 58: 004695802110001.     CrossRef
  • Recent trend of androgen deprivation therapy in newly diagnosed prostate cancer patients: Comparing between high‐ and middle‐income Asian countries
    Jasmine Lim, Mizuki Onozawa, Marniza Saad, Teng Aik Ong, Rohan Malek, Hideyuki Akaza
    Cancer Science.2021; 112(6): 2071.     CrossRef
  • A spatial assessment of prostate cancer mortality-to-incidence ratios among South Carolina veterans: 1999–2015
    Peter Georgantopoulos, Jan M. Eberth, Bo Cai, Gowtham Rao, Charles L. Bennett, Christopher T. Emrich, Kathlyn S. Haddock, James R. Hébert
    Annals of Epidemiology.2021; 59: 24.     CrossRef
  • Assessment of quality benchmarks in adenoma detection in Mexico
    Nancy E. Aguilar-Olivos, Ricardo Balanzá, Fernando Rojas-Mendoza, Rodrigo Soto-Solis, Mario A. Ballesteros-Amozurrutia, Norma González-Uribe, Justo A. Fernández-Rivero
    Endoscopy International Open.2021; 09(06): E796.     CrossRef
  • Favorable Lip and Oral Cancer Mortality-to-Incidence Ratios in Countries with High Human Development Index and Expenditures on Health
    Wen-Wei Sung, Yong-Chen Hsu, Chen Dong, Ying-Ching Chen, Yu-Chi Chao, Chih-Jung Chen
    International Journal of Environmental Research and Public Health.2021; 18(11): 6012.     CrossRef
  • In prostatic transition zone lesions (PI-RADS v2.1): which subgroup should be biopsied?
    Jihae An, Young Joong Kim, Jae Young Seo, Cheol Mog Hwang, Dong Hyun Oh, Mu-Sik Lee, Keum Won Kim
    Egyptian Journal of Radiology and Nuclear Medicine.2021;[Epub]     CrossRef
  • Improvement in the Mortality-to-Incidence Ratios for Gastric Cancer in Developed Countries With High Health Expenditures
    Tzu-Wei Yang, Chi-Chih Wang, Wei-Cheng Hung, Yu-Hsiang Liu, Wen-Wei Sung, Ming-Chang Tsai
    Frontiers in Public Health.2021;[Epub]     CrossRef
  • Provider Barriers and Facilitators of Breast Cancer Guideline-Concordant Therapy Delivery in Botswana: A Consolidated Framework for Implementation Research Analysis
    Tlotlo Ralefala, Lebogang Mokokwe, Swetha Jammalamadugu, Dumelang Legobere, Warona S. Motlhwa, Anthony A. Oyekunle, Surbhi Grover, Frances K. Barg, Lawrence N. Shulman, Yehoda M. Martei
    The Oncologist.2021; 26(12): e2200.     CrossRef
  • Improving Quality Indicator of Melanoma Management – Change of Melanoma Mortality-to-Incidence Rate Ratio Based on a Hungarian Nationwide Retrospective Study
    Máté Várnai, Zoltán Kiss, Rolland Gyulai, Judit Oláh, Péter Holló, Gabriella Emri, András Csejtei, István Kenessey, Angéla Benedek, Zoltán Polányi, Zsófia Nagy-Erdei, Andrea Dániel, Kata Knollmajer, György Rokszin, Ibolya Fábián, Zsófia Barcza, Csaba Polg
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Cancer survival status among male population of Northeast India: A hospital based study
    Manoj Kalita, JagannathDev Sharma, Debanjana Barman, Nizara Baishya, ChandiRam Kalita
    Annals of Oncology Research and Therapy.2021; 1(1): 28.     CrossRef
  • Global Burden of Head and Neck Cancer: Economic Consequences, Health, and the Role of Surgery
    Rolvix H. Patterson, Victoria G. Fischman, Isaac Wasserman, Jennifer Siu, Mark G. Shrime, Johannes J. Fagan, Wayne Koch, Blake C. Alkire
    Otolaryngology–Head and Neck Surgery.2020; 162(3): 296.     CrossRef
  • Trends of National and Subnational Incidence of Childhood Cancer Groups in Iran: 1990–2016
    Mahsima Shabani, Sahar Saeedi Moghaddam, Bahar Ataeinia, Nazila Rezaei, Farnam Mohebi, Bahram Mohajer, Kimiya Gohari, Ali Sheidaei, Farhad Pishgar, Moein Yoosefi, Farzad Kompani, Farshad Farzadfar
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Evaluation of the Cardiac Protection Conferred by Proanthocyanidins in Grape Seeds against Development of Ehrlich Solid Tumors in Mice
    Maha Abdulrahman Aldubayan
    BioMed Research International.2020; 2020: 1.     CrossRef
  • The economic burden of cancer care for Syrian refugees: a population-based modelling study
    Rima A Abdul-Khalek, Ping Guo, Forbes Sharp, Adrian Gheorghe, Omar Shamieh, Tezer Kutluk, Fouad Fouad, Adam Coutts, Ajay Aggarwal, Deborah Mukherji, Ghassan Abu-Sittah, Kalipso Chalkidou, Richard Sullivan
    The Lancet Oncology.2020; 21(5): 637.     CrossRef
  • Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient Empowerment
    Heinz Ludwig, Susie Novis Durie, Angela Meckl, Axel Hinke, Brian Durie
    The Oncologist.2020; 25(9): e1406.     CrossRef
  • Descriptive epidemiology of incidence and mortality of primary liver cancer in 185 countries: evidence from GLOBOCAN 2018
    Rajesh Sharma
    Japanese Journal of Clinical Oncology.2020; 50(12): 1370.     CrossRef
  • Evaluating the Effect of Medicaid Expansion on Black/White Breast Cancer Mortality Disparities: A Difference-in-Difference Analysis
    Jason Semprini, Olufunmilayo Olopade
    JCO Global Oncology.2020; (6): 1178.     CrossRef
  • State-Level Disparity in Lung Cancer Survival in the United States
    Yu-Che Lee, Rafael A. Calderon-Candelario, Gregory E. Holt, Michael A. Campos, Mehdi Mirsaeidi
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Inequalities in the burden of female breast cancer in Brazil, 1990–2017
    Maximiliano Ribeiro Guerra, Mário Círio Nogueira, Deborah Carvalho Malta, Camila Soares Lima Côrrea, Maria de Fatima Marinho de Souza, Maria Paula Curado, Mariana Santos Felisbino-Mendes, Meghan Mooney, Mohsen Naghavi, Maria Teresa Bustamante-Teixeira
    Population Health Metrics.2020;[Epub]     CrossRef
  • Disparities in mortality‐to‐incidence ratios by race/ethnicity for female breast cancer in New York City, 2002‐2016
    Tamar B. Nobel, Charles K. Asumeng, John Jasek, Kellie C. Van Beck, Ruchi Mathur, Baozhen Qiao, Jennifer J. Brown
    Cancer Medicine.2020; 9(21): 8226.     CrossRef
  • Enhanced Cancer-targeted Drug Delivery Using Precoated Nanoparticles
    Lu Yu, Mingyu Xu, Wenwen Xu, Wei Xiao, Xue-hua Jiang, Ling Wang, Huile Gao
    Nano Letters.2020; 20(12): 8903.     CrossRef
  • Oxaliplatin-Based Intra-arterial Chemotherapy in Colo-Rectal Cancer Liver Metastases: A Review from Pharmacology to Clinical Application
    Girolamo Ranieri, Mariarita Laforgia, Patrizia Nardulli, Simona Ferraiuolo, Pasquale Molinari, Ilaria Marech, Cosmo Damiano Gadaleta
    Cancers.2019; 11(2): 141.     CrossRef
  • Melanoma prognosis in the United States: Identifying barriers for improved care
    Zachary H. Hopkins, Christopher Moreno, Ryan Carlisle, Aaron M. Secrest
    Journal of the American Academy of Dermatology.2019; 80(5): 1256.     CrossRef
  • The Coincidence Between Increasing Age, Immunosuppression, and the Incidence of Patients With Glioblastoma
    Erik Ladomersky, Denise M. Scholtens, Masha Kocherginsky, Elizabeth A. Hibler, Elizabeth T. Bartom, Sebastian Otto-Meyer, Lijie Zhai, Kristen L. Lauing, Jaehyuk Choi, Jeffrey A. Sosman, Jennifer D. Wu, Bin Zhang, Rimas V. Lukas, Derek A. Wainwright
    Frontiers in Pharmacology.2019;[Epub]     CrossRef
  • The Mortality-to-Incidence Ratio Is Not a Valid Proxy for Cancer Survival
    Libby Ellis, Aurélien Belot, Bernard Rachet, Michel P. Coleman
    Journal of Global Oncology.2019; (5): 1.     CrossRef
  • National Cancer Mortality-to-Incidence Ratio (MIR) in Iran (2005 - 2014)
    Atieh Akbari, Maryam Khayamzadeh, Reza Salmanian, Ali Ghanbari Motlagh, Gholamreza Roshandel, Maryam Nouri, Mohammad Esmaeil Akbari
    International Journal of Cancer Management.2019;[Epub]     CrossRef
  • The Association between Mortality-to-Incidence Ratios and Health Expenditures in Brain and Nervous System Cancers
    Lee, Sung, Chan, Lee, Chen, Huang, Kwan
    International Journal of Environmental Research and Public Health.2019; 16(15): 2739.     CrossRef
  • miR‐181a/b therapy in lung cancer: reality or myth?
    Cornelia Braicu, Diana Gulei, Roxana Cojocneanu, Lajos Raduly, Ancuta Jurj, Erik Knutsen, George Adrian Calin, Ioana Berindan‐Neagoe
    Molecular Oncology.2019; 13(1): 9.     CrossRef
  • Breast Cancer: Reimbursement Policies and Adoption of New Therapeutic Agents by National Health Systems
    Dario Trapani, Giuseppe Curigliano, Alexandru Eniu
    Breast Care.2019; 14(6): 373.     CrossRef
  • Epidemiology of prostate cancer in Asian countries
    Takahiro Kimura, Shin Egawa
    International Journal of Urology.2018; 25(6): 524.     CrossRef
  • Cause-of-death statistics in 2016 in the Republic of Korea
    Hyun-Young Shin, Ji-Youn Lee, Jee-Eun Kim, Seokmin Lee, Heejo Youn, Heyran Kim, Jeonghun Lee, Min Sim Park, Sun Huh
    Journal of the Korean Medical Association.2018; 61(9): 573.     CrossRef
  • Is mortality-to-incidence ratio associated with health disparity in pancreatic cancer? A cross-sectional database analysis of 57 countries
    Hsiang-Lin Lee, Cheng-Ming Peng, Cheng-Yu Huang, Shin-Yi Wu, Ming-Chang Tsai, Chi-Chih Wang, Sung-Lang Chen, Chun-Che Lin, Chien-Ning Huang, Wen-Wei Sung
    BMJ Open.2018; 8(7): e020618.     CrossRef
Epidemiol Health : Epidemiology and Health
© Korean Society of Epidemiology.